PRR14 overexpression promotes cell growth, epithelial to mesenchymal transition and metastasis of colon cancer via the AKT pathway


Autoři: Fangfang Li aff001;  Chundong Zhang aff003;  Lijuan Fu aff001
Působiště autorů: Joint International Research Laboratory of Reproduction and Development of the Ministry of Education, Department of Reproductive Biology, Chongqing Medical University, Chongqing, China aff001;  Medical Research Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China aff002;  Department of Biochemistry and Molecular Biology, Chongqing Medical University, Chongqing, China aff003;  Department of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China aff004
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0218839

Souhrn

Background

PRR14 (Proline rich protein 14) was firstly identified for its ability to specify and localize heterochromatin during cell cycle progression. Aberrant expression of PRR14 is associated with the tumorigenesis and progression of lung cancer. However, its involvement in colon cancer remains unknown. Herein, we report the role of PRR14 in colon cancer.

Methods

Colon cancer tissue microarray was used to analyze and compare the expression of PRR14 among some clinicopathological characteristics of colon cancer. HCT116 and RKO cells were transfected with siRNA to downregulate PRR14 expression. The roles of PRR14 in proliferation, migration and invasion of the cell lines were determined using cell counting kit-8, colony formation assay, wound healing assay and transwell assays respectively. The expression of PRR14 was measured using immunofluorescence, qRT- PCR and western blot. Epithelial-mesenchymal transition (EMT) markers were determined by western blot.

Results

PRR14 was highly expressed in colon cancer tissues, and the expression level was correlated with tumor size, distant metastasis and Tumor Node Metastasis stages. Functional study revealed that downregulation of PRR14 inhibited colon cancer cells growth, migration and invasion. Furthermore, knockdown of PRR14 inhibited epithelial-mesenchymal transition (EMT) process, cell cycle-associated proteins expression and p-AKT level.

Conclusion

PRR14 may promote the progression and metastasis of colon cancer, and may be a novel prognostic and therapeutic marker for the disease.

Klíčová slova:

Apoptosis – Cell cycle and cell division – Colorectal cancer – Gene expression – Metastasis – Small interfering RNAs – Cancer cell migration – Cell cycle inhibitors


Zdroje

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502. doi: 10.1016/S0140-6736(13)61649-9 24225001

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi: 10.3322/caac.21338 26808342

3. Poleshko A, Mansfield KM, Burlingame CC, Andrake MD, Shah NR, Katz RA. The human protein PRR14 tethers heterochromatin to the nuclear lamina during interphase and mitotic exit. Cell Rep. 2013;5(2):292–301. doi: 10.1016/j.celrep.2013.09.024 24209742

4. Ball LJ, Kuhne R, Schneider-Mergener J, Oschkinat H. Recognition of proline-rich motifs by protein-protein-interaction domains. Angew Chem Int Ed Engl. 2005;44(19):2852–69. doi: 10.1002/anie.200400618 15880548

5. Li SS. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem J. 2005;390(Pt 3):641–53. doi: 10.1042/BJ20050411 16134966

6. Poleshko A, Katz RA. Specifying peripheral heterochromatin during nuclear lamina reassembly. Nucleus. 2014;5(1):32–9. doi: 10.4161/nucl.28167 24637393

7. Yang M, Yuan ZM. A novel role of PRR14 in the regulation of skeletal myogenesis. Cell Death Dis. 2015;6:e1734. doi: 10.1038/cddis.2015.103 25906157

8. Yang M, Lewinska M, Fan X, Zhu J, Yuan ZM. PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis. Oncogene. 2016;35(42):5527–38. doi: 10.1038/onc.2016.93 27041574

9. Xiao S, Yang M. Discovery of a novel target for cancer: PRR14. Cell Death Dis. 2016;7(12):e2502. doi: 10.1038/cddis.2016.401 27906191

10. He Yu PZ, Dan Li, Dan Liu, Weimin Li. PRR14 is an independent predictor of poor prognosis in resected non-small cell.pdf. Int J Clin Exp Pathol. 2017;10(6):6735–42.

11. Yang M, Long MJ, Shi XL, Yuan ZM, Su H. PRR14, a novel regulator of Ras signaling pathway. Cancer Research. 2017;77.

12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi: 10.1093/nar/gkx247 28407145

13. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80. doi: 10.1593/neo.07112 17356713

14. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27(2):83–90. doi: 10.1007/s10585-010-9305-4 20143136

15. Kar S. Unraveling Cell-Cycle Dynamics in Cancer. Cell Syst. 2016;2(1):8–10. doi: 10.1016/j.cels.2016.01.007 27136683

16. Moiseeva TN, Bakkenist CJ. Regulation of the initiation of DNA replication in human cells. DNA Repair (Amst). 2018;72:99–106.

17. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23. doi: 10.1038/nature03097 15549093

18. Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212–26. doi: 10.1016/j.tcb.2018.12.001 30594349

19. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi: 10.1038/s41580-018-0080-4 30459476

20. Yang Y, Wang G, Zhu D, Huang Y, Luo Y, Su P, et al. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer. International Journal of Oncology. 2017;51(2):515–24. doi: 10.3892/ijo.2017.4044 28627611

21. Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, et al. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci U S A. 2010;107(24):10920–5. doi: 10.1073/pnas.0914776107 20534451

22. Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adh Migr. 2011;5(5):421–30. doi: 10.4161/cam.5.5.17723 21975551

23. Jacquemet G, Hamidi H, Ivaska J. Filopodia in cell adhesion, 3D migration and cancer cell invasion. Curr Opin Cell Biol. 2015;36:23–31. doi: 10.1016/j.ceb.2015.06.007 26186729

24. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008;582(14):2102–11. doi: 10.1016/j.febslet.2008.03.039 18396168

25. Cantley LC. The phosphoinositide 3-kinase pathway.pdf. SCIENCE. 2002 296(31):1655–7.

26. Del Piccolo N, Hristova K. Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells. Biophys J. 2017;113(6):1353–64. doi: 10.1016/j.bpj.2017.06.029 28734476

27. Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer. 2011;2(3):261–74. doi: 10.1177/1947601911408079 21779497


Článek vyšel v časopise

PLOS One


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se